To investigate the anti-cancer efficiency of triciribine, an AKT inhibitor, co-treatment with rapamycin (ABI-009) was applied to both GBM cell line (U251) and the neuroblastoma cell line (SH-SY5Y) [173]. This evidence concerns the gene AKT1 and cancer.